(Q42680844)

4 November 2017

Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites (English)

1 reference

4 November 2017

1 reference

K M Jorga

1

1 reference

4 November 2017

J M Kroodsma

2

1 reference

4 November 2017

B Fotteler

3

1 reference

4 November 2017

P Heizmann

4

1 reference

4 November 2017

J Meyer

5

1 reference

4 November 2017

M C Rasch

6

1 reference

4 November 2017

J van Hattum

7

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

Clinical Pharmacology & Therapeutics

4 November 2017

1 reference

4 November 2017

63

1 reference

4 November 2017

6

1 reference

4 November 2017

646-654

1 reference

Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Clinical pharmacokinetics in patients with liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Pharmacokinetics in liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Liver disease and drug disposition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Treatment of Hepatic Coma by Exchange Blood Transfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

6,6′‐Azopurine, a Potent In Vitro Inhibitor of Rabbit Liver Aldehyde Oxidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

Clearance concepts in pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990088-1

10.1016/S0009-9236(98)90088-1

7 January 2021

Identifiers

DOI

1 reference

4 November 2017

1 reference